Japanese drugmaker Astellas Pharma Inc. has agreed to acquire Iveric Bio Inc., which develops drugs to treat age-related blindness, for about $5.9 billion.
Astellas Pharma Inc. says it will buy U.S. pharmaceutical company Iveric Bio Inc., which focuses on ophthalmology treatments, for about $5.9 billion, as the Japanese drugmaker continues its merger and acquisition drive.
TOKYO Japan’s Astellas Pharma said on Monday it agreed to buy U.S. drugmaker Iveric Bio Inc for about $5.9 billion in its biggest acquisition, giving it…
Japanese drugmaker Astellas Pharma Inc. has agreed to acquire Iveric Bio Inc., which develops drugs to treat age-related blindness, for about $5.9 billion.